Monoclonal Antibody-Based Therapies for AQP4-Positive NMOSD — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Monoclonal Antibody-Based Therapies for AQP4-Positive NMOSD — Stella

Recruiting

Back to NMO Spectrum Disorder trials

Trial locations(1 site)

China

Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei

Key details

Sponsor

Tongji Hospital

Enrollment target

~200 participants

Started

July 2025

Primary completion

June 2027

Age range

18 Years – 65 Years

Last updated September 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov